Success Metrics

Clinical Success Rate
78.6%

Based on 11 completed trials

Completion Rate
79%(11/14)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
3(21%)

Phase Distribution

Ph phase_1
5
36%
Ph phase_2
9
64%

Phase Distribution

5

Early Stage

9

Mid Stage

0

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
5(35.7%)
Phase 2Efficacy & side effects
9(64.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

78.6%

11 of 14 finished

Non-Completion Rate

21.4%

3 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(11)
Terminated(3)

Detailed Status

Completed11
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
78.6%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (35.7%)
Phase 29 (64.3%)

Trials by Status

completed1179%
terminated321%

Recent Activity

0 active trials
Showing 5 of 14
terminatedphase_2

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

NCT01676935
terminatedphase_2

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

NCT01690195
completedphase_2

A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

NCT01655680
completedphase_2

A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

NCT01678755
completedphase_2

Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia

NCT01095562
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT01676935Phase 2

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Terminated
NCT01690195Phase 2

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Terminated
NCT01655680Phase 2

A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

Completed
NCT01678755Phase 2

A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

Completed
NCT01095562Phase 2

Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Completed
NCT01834638Phase 2

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Terminated
NCT01527916Phase 2

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Completed
NCT01549834Phase 2

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Completed
NCT00948909Phase 2

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

Completed
NCT01482845Phase 1

A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease

Completed
NCT00959634Phase 1

Pharmacokinetic Study of ABT-126 in Healthy Volunteers

Completed
NCT00867399Phase 1

A Safety and Tolerability Study of ABT-126 in Elderly

Completed
NCT01043458Phase 1

Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia

Completed
NCT00912431Phase 1

Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy Volunteers

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14